Sangamo Therapeutics
Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.
-
One-Time gene therapy could change fabry disease treatment
Disease control CompletedThis trial tested a new gene therapy called ST-920 for Fabry disease, a rare genetic condition. The therapy uses a harmless virus to deliver a working gene that helps the body produce an enzyme it's missing. 36 adults with Fabry disease received a single intravenous dose and were…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene-Editing hope: could BIVV003 free sickle cell patients from pain crises?
Disease control CompletedThis early-phase trial tested a new gene therapy called BIVV003 in 7 adults with severe sickle cell disease. The treatment uses the patient's own stem cells, which are gene-edited in a lab and then infused back after chemotherapy. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:44 UTC